Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Enzo Biochem Dividend Announcement
• Enzo Biochem announced a annually dividend of $0.10 per ordinary share which will be made payable on 2024-12-02. Ex dividend date: 2024-11-15
• Enzo Biochem annual dividend for 2024 was $0.10
• Enzo Biochem's trailing twelve-month (TTM) dividend yield is 9.52%
Enzo Biochem Dividend History
| Ex-Div date | Dividend amount | Dividend type | Pay date |
|---|---|---|---|
| 2024-11-15 | $0.10 | annually | 2024-12-02 |
| 1995-06-29 | $0.06 | annually |
Enzo Biochem Dividend per year
Enzo Biochem Dividend Yield
Enzo Biochem current trailing twelve-month (TTM) dividend yield is 9.52%. Interested in purchasing Enzo Biochem stock? Use our calculator to estimate your expected dividend yield:
Enzo Biochem Financial Ratios
Enzo Biochem Dividend FAQ
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Place an order: Use the brokerage's trading platform to place an order to buy Enzo Biochem stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.